Colchicine reduces postoperative atrial fibrillation: Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy

Massimo Imazio*, Antonio Brucato, Paolo Ferrazzi, Maria Elena Rovere, Anna Gandino, Roberto Cemin, Stefania Ferrua, Riccardo Belli, Silvia Maestroni, Caterina Simon, Edoardo Zingarelli, Alberto Barosi, Fabrizio Sansone, Davide Patrini, Ettore Vitali, Rita Trinchero, David H. Spodick, Yehuda Adler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background-: Inflammation and pericarditis may be contributing factors for postoperative atrial fibrillation (POAF), and both are potentially affected by antiinflammatory drugs and colchicine, which has been shown to be safe and efficacious for the prevention of pericarditis and the postpericardiotomy syndrome (PPS). The aim of the Colchicine for the Prevention of the Post-Pericardiotomy Syndrome (COPPS) POAF substudy was to test the efficacy and safety of colchicine for the prevention of POAF after cardiac surgery. Methods and Results-: The COPPS POAF substudy included 336 patients (mean age, 65.7±12.3 years; 69% male) of the COPPS trial, a multicenter, double-blind, randomized trial. Substudy patients were in sinus rhythm before starting the intervention (placebo/colchicine 1.0 mg twice daily starting on postoperative day 3 followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ge;70 kg, halved doses for patients <70 kg or intolerant to the highest dose). The substudy primary end point was the incidence of POAF on intervention at 1 month. Despite well-balanced baseline characteristics, patients on colchicine had a reduced incidence of POAF (12.0% versus 22.0%, respectively; P=0.021; relative risk reduction, 45%; number needed to treat, 11) with a shorter in-hospital stay (9.4±3.7 versus 10.3±4.3 days; P=0.040) and rehabilitation stay (12.1±6.1 versus 13.9±6.5 days; P=0.009). Side effects were similar in the study groups. Conclusion-: Colchicine seems safe and efficacious in the reduction of POAF with the potentiality of halving the complication and reducing the hospital stay. Clinical Trial Registration-: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00128427.

Original languageEnglish
Pages (from-to)2290-2295
Number of pages6
JournalCirculation
Volume124
Issue number21
DOIs
StatePublished - 22 Nov 2011

Keywords

  • atrial fibrillation
  • cardiac surgery
  • colchicine
  • postpericardiotomy syndrome
  • prevention

Fingerprint

Dive into the research topics of 'Colchicine reduces postoperative atrial fibrillation: Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy'. Together they form a unique fingerprint.

Cite this